MedTrace Logo

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization

NCT04397718 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2022-06-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.

Conditions

Interventions

DRUG

Degarelix

Degarelix is an FDA-approved drug for prostate cancer

OTHER

Saline

09% Saline

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Matthew B. Rettig, MD · VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-06
Primary Completion
2021-06-08
Completion
2021-06-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04397718 on ClinicalTrials.gov